	Stem Cell-Derived Extracellular Vesicles in Bladder Cancer: Diagnostic Potential and Therapeutic Challenges. Int J Nanomedicine Lu W, Fu P, Li C, Lou K, Feng S, Wang Y. PMID: 42999830 [PubMed - indexed for MEDLINE]
	Retraction notice to "Safety and Efficacy Of Sorafenib In Patients With Castrate Resistant Prostate Cancer: A Phase II Study" [Urologic Oncology: Seminars and Original Investigations 28 (2010) 21-27]. Urol Oncol Safarinejad MR. PMID: 42998955 [PubMed - as supplied by publisher]
	Enhanced image quality and interpretation efficiency of voxelwise-computed diffusion-weighted imaging for bladder cancer VI-RADS assessment. Abdom Radiol (NY) Zhang M, Chen C, Zhao Q, Zeng X, Cai W, Ma Z. PMID: 42998145 [PubMed - as supplied by publisher]
	Epigenetic reprogramming in Urothelial bladder cancer: mechanisms, biomarkers, and therapeutic opportunities. Epigenetics Yuanjiang Q, Liming Y. PMID: 42998129 [PubMed - indexed for MEDLINE]
	Navigating the current and future perioperative treatment landscape of muscle-invasive bladder cancer (MIBC). Transl Cancer Res Azad F, Kevu E, Aragon-Ching JB. PMID: 42997899 [PubMed]
	Radiomics-augmented lesion characterization on prostate multiparametric magnetic resonance imaging: first-order features and ratio metrics may improve diagnostic performance in prostate cancer. Quant Imaging Med Surg Niessen C, Haas M, Burger M, Engelmann SU, Eckl C, Vogel E, Schnabel MJ, Stroszczynski C, Weber F, Haas SL, Mayr R, Pickl C. PMID: 42997770 [PubMed]
	Prognostic value of neutrophil-to-lymphocyte ratio in renal cell carcinoma: an updated systematic review and meta-analysis. Transl Androl Urol Luo Z, Lin Z, Chen X, Kuang Z. PMID: 42997244 [PubMed]
	A transcriptomic signature of mechanical-memory-related genes predicts progression in prostate cancer. Transl Androl Urol Sun T, Wu Y, Chen H, Wang F. PMID: 42997240 [PubMed]
	Multidisciplinary management of metastatic renal cell carcinoma: a narrative review. Transl Androl Urol Fribourg-Liendo RA, Kothari A, Yip W. PMID: 42997216 [PubMed]
	The role of the p53 signaling pathway in prostate cancer. Transl Androl Urol Shi R, Fu H, Wang X, Ye C, Ji X, Zhao H, Zhang Y, Fan D. PMID: 42997210 [PubMed]
	A 5-gene mutation signature predicts response to atezolizumab in metastatic bladder urothelial carcinoma. Transl Androl Urol Han D, Wu C, Wang D, Jin H, Liu W. PMID: 42997198 [PubMed]
	Development and internal validation of a clinical model to increase the diagnostic probability of prostate cancer in patients with prostate-specific antigen levels of 4.0-10.0 ng/mL. Transl Androl Urol Xu B, Jiang J, Zhang L, Ge Q, Liu J, Zhou J. PMID: 42997172 [PubMed]
	ASO Visual Abstract : Performance of (68)Ga-PSMA-11 PET/CT for Diagnosing Tumor Thrombus and Predicting Response to Pembrolizumab and Axitinib in Patients with Renal Cell Carcinoma: A Pilot, Retrospective Study. Ann Surg Oncol Lin BH, Zeng CL, Wu XH, Gao RC, Qiu QR, Chen YH, Xue XY, Zheng QS, Chen SH, Wei Y, Xu N. PMID: 42995365 [PubMed - as supplied by publisher]
	ASO Visual Abstract: Full-field Optical Coherence Tomography for Immediate Analysis of Prostate Biopsy Cores: A new Step Towards Real-time Cancer Diagnosis. Ann Surg Oncol Anract J, Larnaudie L, Diamand R, Chen W, Duquesne I, Sibony M, Barry Delongchamps N. PMID: 42995359 [PubMed - as supplied by publisher]
	Effect of positive surgical margin characteristics on biochemical failure following robot-assisted radical prostatectomy. J Robot Surg Demirel D, Ceviz K, Polat ME, Arabac, Ozden C. PMID: 42995345 [PubMed - indexed for MEDLINE]
	Sex-disaggregated Outcomes and Safety Reporting in Perioperative Systemic Therapy for Muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol Oncol Mari A, Giudici S, Grobet-Jeandin É, Claps F, Contieri R, Giudice FD, Scilipoti P, , Cerrato C, Garino D, Crocerossa F, Alcaraz A, Aning J, Breda A, Brouwer OR, Fankhauser C, Gandaglia G, Giannarini G, Gomez-Rivas J, Grimm MO, Moschini M, Sanguedolce F, Mir MC, Gallioli A, Mertens L, Albisinni S, Soria F, Pradere B, Rouprêt M, Volpe A, European Association of Urology (EAU) YAU urothelial carcinoma working group and the European Section of Urologic-Oncology (ESOU) of EAU. PMID: 42995099 [PubMed - as supplied by publisher]
	Diagnostic value of multiparametric MRI radiomics combined with serum PSA and tissue P504S for prostate cancer. Medicine (Baltimore) Zhang L, Zhao D, Bai Y, Zhao D, Li J. PMID: 42994818 [PubMed - indexed for MEDLINE]
	MRI-guided HDR brachytherapy or integrated VMAT boost for tumour-targeted dose escalation in localised prostate cancer: long-term results of the TARGET study. Radiother Oncol Padayachee J, Sanmamed NS, Ye XY, Liu ZA, Lee J, Berlin A, Craig T, Lao B, Rink A, Bayley A, Catton C, Foltz W, McPartlin A, Ghai S, Glicksman RM, Gospodarowicz M, Warde P, Ménard C, Chung P. PMID: 42994518 [PubMed - as supplied by publisher]
	Methionine restriction inhibits EZH2-mediated GSDMD methylation to promote pyroptosis in prostate cancer. Proc Natl Acad Sci U S A Liu SY, Ming DJ, Xu YH, Li BH, Shi MH, Xi S, Cui JL, Yang JY, Xiong X, He SH, Wang SC, Wang DQ, Zhang J, Weng H, Zeng XT, Yuan S. PMID: 42993569 [PubMed - indexed for MEDLINE]
	Prognostic impact of primary Gleason pattern 5 in patients with low-volume metastatic hormone-sensitive prostate cancer treated with upfront ARPI-based doublet therapy: a real-world multicenter international collaborative study. Int J Clin Oncol Yamada Y, Sato K, Luo HL, Wang HJ, Liu HY, Chang YL, Su YL, Wu CT, Yu KJ, Lin PH, Liu CY, Ho DR, Huang YC, Tsujino T, Saito S, Maenosono R, Nishimura K, Fukushima T, Nakamura K, Yamamoto S, Arai T, Sato H, Higuchi K, Kurozumi A, Takei A, Kanesaka M, Ando K, Kurokawa K, Kanaoka S, Takeshita N, Yoneda K, Hino D, Tamura T, Sazuka T, Imamura Y, Mikami K, Nakamura K, Fukasawa S, Naya Y, Nagata M, Komaru A, Tobe T, Suzuki N, Azuma H, Sakamoto S. PMID: 42993239 [PubMed - as supplied by publisher]

Articles 1 - 20 / 182793

Page 1 of 9140



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy